A good week for European biotech in the US, which began with Calliditas Therapeutics AB's Tarpeyo getting accelerated approval for immunoglobulin A nephropathy (IgAN), was rounded off by argenx N.V. getting the green light for Vyvgart in generalized myasthenia gravis (gMG).
First to the eagerly-anticipated approval by the US Food and Drug Administration of Vyvgart(efgartigimod) on 17 December for adults who...